(Total Views: 615)
Posted On: 10/20/2020 6:28:08 PM
Post# of 155514
What Was So Great About It?
1) continue s/c trial with no changes, no problems detected, no safety issues,
2) another interim analysis at 293 vs recommending "continue to 390. This implies expected Statistical Significance from the DSMC.
3) DSMC recommendations will help to speed up s/c enrollment, because sick potential enrollees will be told about it, and be told about iEND and m/m results and it's a shot not an IV. And the will be told (hopefully) thant remdesivir is not effective nor safe.
4) other countries will be made aware of the DSMC recommendations and hopefully at least 1 or 2 will now quickly enter a pathway for their own use and approval of Leronlimab.
5) Nader said he will be contacted the Philippians and the UK right away regarding possible approvals now, based upon all positive data and DSMC.
6) there's more, do some DD and discover more.
1) continue s/c trial with no changes, no problems detected, no safety issues,
2) another interim analysis at 293 vs recommending "continue to 390. This implies expected Statistical Significance from the DSMC.
3) DSMC recommendations will help to speed up s/c enrollment, because sick potential enrollees will be told about it, and be told about iEND and m/m results and it's a shot not an IV. And the will be told (hopefully) thant remdesivir is not effective nor safe.
4) other countries will be made aware of the DSMC recommendations and hopefully at least 1 or 2 will now quickly enter a pathway for their own use and approval of Leronlimab.
5) Nader said he will be contacted the Philippians and the UK right away regarding possible approvals now, based upon all positive data and DSMC.
6) there's more, do some DD and discover more.
(4)
(0)
